Research Objective:To investigate the efficacy and safety of the "total neoadjuvant chemoradiotherapy combined with immunotherapy" regimen for the treatment of locally advanced rectal cancer with high-risk features for recurrence.
Study Design:A single-arm, multicenter clinical study.
Study Population: Patients with locally advanced rectal cancer presenting with high-risk features for local recurrence.
Pathologically confirmed rectal adenocarcinoma;
Mid-low rectal cancer, with the lower edge of the tumor located within 12 cm from the anal verge;
Magnetic resonance imaging (MRI) suggests locally advanced rectal cancer (T3 or T4 and M0), accompanied by at least one of the following risk factors: cT4, N2, lymphovascular invasion, involvement of the mesorectal fascia, or enlarged lateral lymph nodes (short-axis diameter > 8 mm); patients with potentially resectable disease;
Polymerase chain reaction (PCR) testing indicates microsatellite stability (MSS) type;
Recurrent rectal cancer;
Synchronous colorectal cancer;
Pregnant or lactating patients;
History of other malignant tumors;
Single group
PD-1
Drugpatients will receive short-course chemotherapy and concurrent PD-1
pathological complete response rate
the incidence of no tumor residual after the treatment
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
